While there are RNAi products on the marketplace, with Alnylam becoming the first company to get a product approved in 2018, it is difficult to get this class of drug distributed through the brain ...

Arrowhead Pharmaceuticals, Inc. ( (ARWR) ) has released its Q4 earnings. Here is a breakdown of the information Arrowhead Pharmaceuticals, Inc.

We recently compiled a list of the 10 Worst Performing Healthcare Stocks in 2024. In this article, we are going to take a ...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...

RNA therapeutics promise rapid, personalized and flexible treatments against multiple diseases. In this article, we will ...

Rznomics, Inc. announced to secure its expanded access program (EAP) from the United States Food and Drug Administration (FDA) for RZ-001, ...

Kaye, who has held positions at Genzyme and Sarepta Therapeutics — where he led development of the Duchenne muscular ...

The company is working with a Nucleic Acid Therapy Accelerator in the U.K. to more quickly develop cancer drugs.

RNAi is a natural process that occurs in plants ... and now has a technology platform which investors think will pay off. Despite having no products approved yet, the company has a market ...

This strategic partnership and the recognition from the recent study represent a major step forward in Bioz's mission to support the global research community. By enhancing the visibility of ...

Arrowhead has entered a worldwide licensing and partnership agreement with Sarepta Therapeutics for rare genetic disease ...

Fintel reports that on November 26, 2024, RBC Capital initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a ...